Beyond Blood Sugar: Why Type 1 Diabetes Care Is Evolving

When insulin was discovered over a century ago, it transformed Type 1 diabetes from a fatal diagnosis into a manageable condition. Yet today, people with Type 1 diabetes continue to face elevated cardiovascular risk—meaning higher rates of heart attack and stroke—compared to the general population. This increased risk persists even when blood sugar control appears adequate by traditional measures.

This gap between good glucose management and remaining heart disease risk has prompted researchers to look deeper. The answer, evidence suggests, lies beyond insulin and blood sugar alone.

Recent research has identified several interconnected mechanisms that may explain excess cardiovascular risk in Type 1 diabetes:

Glycemic variability—the constant fluctuation between high and low blood sugar levels—appears to contribute independently to heart disease risk, separate from average glucose levels. Weight gain associated with insulin therapy, insulin resistance (when the body doesn't respond well to insulin's effects), and imbalances in other hormones also play roles. These factors don't exist in isolation; they interact in ways that researchers are still working to fully understand.

Recognition of these multiple risk factors has led to the development of additional medications beyond insulin that target different pathways involved in diabetes and heart disease. Rather than relying on insulin therapy alone, the approach is broadening to address the full spectrum of metabolic changes that occur in Type 1 diabetes.

Current treatments aim to smooth blood sugar swings, support healthy weight, improve insulin sensitivity, and correct hormonal imbalances—all with the goal of reducing cardiovascular risk.

While the science pointing toward these risk factors is solid, a critical gap remains: long-term data on whether treating these underlying mechanisms actually reduces heart attacks, strokes, and other major cardiovascular events in people with Type 1 diabetes.

Researchers emphasize the importance of gathering evidence on hard cardiovascular outcomes—meaning actual reductions in heart disease and death—rather than improvements in intermediate measures alone. This ongoing research will help clarify which new approaches offer the greatest benefit and for whom they work best.

Source: Endocrinology and metabolism clinics of North America. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.